Telix Pharmaceuticals has reaffirmed that it will pass US$1 billion in revenue and other income this year. Its third-quarter sales were consistent with the previous quarter, and it is working through a US$1.65 billion merger.

BioNTech has opened its clinical-scale mRNA manufacturing and research facility at La Trobe University's Bundoora campus, nearly three years after it first announced the plan.

As Australia's Biggest Week in Biotech approaches, AusBiotech is celebrating four emerging companies that have joined its growing national community through AusBiotech Connect, a membership designed to support the next generation of biotechnology, medical technology and health technology innovators.

Eleven life sciences companies will spend three minutes each making their case to investors on the Gold Coast this month. They will have no slides to lean on.

Australian biotech science has never been stronger, but the conditions around it are shifting. US drug pricing, China's rise and a rethink of American research funding are changing where medicines are discovered, developed and financed.

Tofflon Science and Technology Group will show a scale model of a modular CAR-T manufacturing facility at AusBiotech International 2026 on the Gold Coast.

Racura Oncology has been given the go-ahead to raise the dose in its HARNESS-1 lung cancer trial after a safety review found no dose-limiting toxicities in the first patients treated.

Perth-based regenerative medicine company Orthocell says its nerve repair device could open a new market in prostate cancer surgery.

The PALACROS research program was formally launched in Amsterdam this week. It brings together leading European hospitals, researchers, patient organisations, and industry partners to improve treatment for patients with locally advanced pancreatic cancer.

Argent BioPharma has recast itself as an immune science company. In an update to shareholders, it said it will now focus its resources and research on inflammatory disease after licensing CannEpil to a global partner.

NeuroScientific Biopharmaceuticals has announced that US regulators have largely endorsed its plans for a Phase 2 trial of a stem cell therapy in people with Crohn's disease who have not responded to existing treatments.

A new generation of Australian life sciences innovation will take the stage on the Gold Coast this month, with AusBiotech announcing the 2026 participants in its Early-Stage Innovation Forum.

An experimental treatment developed by Syntara improved movement in people at high risk of developing Parkinson's disease, and the benefit lasted three months after treatment stopped, according to new results from a Phase 2 trial.

Perth-based company PYC Therapeutics will take early human data on its polycystic kidney disease drug to the American Society of Nephrology conference in Denver on 22 October.

Clarity Pharmaceuticals has reached its recruitment target for the main group of the expansion phase of its SECuRE trial, and says it is already planning a registrational Phase 3 study of its copper isotope therapy for advanced prostate cancer.

An Australian company has taken one of the country's top design honours for a machine built to solve one of healthcare's most stubborn cleaning problems.

Average pay for chief executives of Australia's largest listed health care and biotechnology companies rose for a second consecutive year in 2026, while average pay at the smallest companies fell, according to a new benchmarking report.